Ratings Treace Medical Concepts, Inc.

Equities

TMCI

US89455T1097

Market Closed - Nasdaq Other stock markets 04:00:02 2024-04-23 pm EDT			5-day change	1st Jan Change
10.84 ^USD	-2.34%		-4.91%	-14.98%

Mar. 25	Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction	MT
Feb. 27	Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2026.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in debt and has limited leeway for investment
The company's enterprise value to sales, at 3.36 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
TREACE MEDICAL CONCEPTS, INC.	-14.98%	687M	C-
SHOCKWAVE MEDICAL, INC.	+72.39%	12.33B	B-
PENUMBRA, INC.	-18.22%	7.86B	C+
MASIMO CORPORATION	+16.84%	7.11B	C-
GETINGE AB	+3.48%	5.77B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+8.16%	5.1B	D+
APT MEDICAL INC.	+19.97%	4.29B	-
ASAHI INTECC CO., LTD.	-19.61%	3.92B	B-
INARI MEDICAL, INC.	-42.79%	2.2B	C
SKAN GROUP AG	+0.87%	1.92B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes